Custom Mazdutide CAS 2259884-03-0: Top China Suppliers and Factory for Dual GCG/GLP-1 Agonist for Weight Loss Manufacturer, Quotes
Product Description
Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for weight loss, offering a unique mechanism that enhances weight-loss efficacy while reducing visceral fat and delivering comprehensive metabolic benefits, named by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025.
Therapeutic Areas
With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs
With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to reap the rewards in the near term.
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s dual GLP-1/glucagon (GCP) receptor agonist mazdutide for chronic weight management in Chinese adults who are overweight or have obesity.
Crucially, patients must also have at least one weight-related comorbidity, such as high blood sugar or blood pressure, according to a statement from the country’s drug regulator.
Outlook & Development
The green light earns mazdutide the distinction of being the world’s first dual GCG/GLP-1 med, Innovent said in a June 27 press release. Innovent paid an undisclosed sum to secure the Chinese rights to mazdutide from Lilly in 2019, while Lilly continues to hold the rights to the metabolic drug outside of China, where it has yet to win approval.
Mazdutide, as a new entrant in the booming GLP-1 scene for obesity, recently ranked among Fierce Pharma’s top 10 most anticipated drug launches of 2025. That report leveraged data on prospective launches from intelligence and analytics firm Evaluate, which has estimated that the drug could reach $1.3 billion in 2030 sales.
By targeting the GCG receptor, Lilly and Innovent figure mazdutide should help increase the body’s energy expenditure, spurring changes in the liver, brain and white and brown adipose tissue that complement the reduced energy intake triggered by GLP-1 activation.
China’s drug regulator based its approval on data from Innovent’s phase 3 GLORY-1 study in more than 600 adults in China who are overweight or obese. At the study’s 48-week mark, patients on mazdutide 4 mg, mazdutide 6 mg and placebo achieved an average weight loss relative to baseline of 12%, 14.8% and 0.5%, respectively.
What is Mazdutide?
Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for weight loss. It is designed to enhance weight-loss efficacy, reduce visceral fat, and provide comprehensive metabolic benefits.
Which companies are involved in the development of Mazdutide?
Mazdutide was developed through a partnership between Eli Lilly and Innovent Biologics. Innovent secured the Chinese rights in 2019, while Eli Lilly retains the development and commercialization rights outside of China.
Who is eligible for Mazdutide treatment in China?
It is approved for Chinese adults who are overweight or have obesity, provided they also have at least one weight-related comorbidity, such as high blood pressure or high blood sugar.
How does the dual GCG/GLP-1 mechanism work?
By targeting the GCG receptor, Mazdutide helps increase the body’s energy expenditure and spurs positive changes in the liver, brain, and adipose tissues. This complements the reduced energy intake that is typically triggered by GLP-1 activation.
What were the key results from the phase 3 GLORY-1 study?
In the 48-week phase 3 GLORY-1 study involving over 600 adults in China, patients taking Mazdutide 4 mg and 6 mg achieved an average weight loss of 12% and 14.8% respectively, compared to just 0.5% for those on a placebo.
What is the sales and market outlook for Mazdutide?
Named by Fierce Pharma as one of the top ten most anticipated drugs globally in 2025, Evaluate estimates that Mazdutide could reach approximately $1.3 billion in sales by the year 2030.
